The DOI matches its Crossref record.
Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advanced glycation endproducts—role in pathology of diabetic complications
Ahmed, N. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.09.004 · Cited by 1,455
Diabetic neuropathy: Mechanisms to management
Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.05.005 · Cited by 790
Extracellular Matrix Metabolism in Diabetic Nephropathy
Mason, R. M., & Wahab, N. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065640.77499.d7 · Cited by 655
Gilbert, R. E., & Cooper, M. E. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00721.x · Cited by 649
Self-citationSchalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both?
Vlassara, H., & Uribarri, J. (2014) · Current Diabetes Reports · doi:10.1007/s11892-013-0453-1 · Cited by 594
Pathogenesis, prevention, and treatment of diabetic nephropathy
Cooper, M. E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01346-4 · Cited by 560
Self-citationOldfield, M. D., Bach, L. A., Forbes, J. M., Nikolic-Paterson, D., McRobert, A., Thallas, V., Atkins, R. C., Osicka, T., Jerums, G., & Cooper, M. E. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11951 · Cited by 472
Self-citationPyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
Degenhardt, T. P., Alderson, N. L., Arrington, D. D., Beattie, R. J., Basgen, J. M., Steffes, M. W., Thorpe, S. R., & Baynes, J. W. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00207.x · Cited by 378
AGE, RAGE, and ROS in Diabetic Nephropathy
Tan, A. L. Y., Forbes, J. M., & Cooper, M. E. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.006 · Cited by 368
Self-citationSchrijvers, B. F., De Vriese, A. S., & Flyvbjerg, A. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0018 · Cited by 353
The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases
Maessen, D. E. M., Stehouwer, C. D. A., & Schalkwijk, C. G. (2015) · Clinical Science · doi:10.1042/cs20140683 · Cited by 334
Diabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Pharmacological Inhibition of Diabetic Retinopathy
Kern, T. S., & Engerman, R. L. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1636 · Cited by 277
Forbes, J. M., Cooper, M. E., Thallas, V., Burns, W. C., Thomas, M. C., Brammar, G. C., Lee, F., Grant, S. L., Burrell, L. M., Jerums, G., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.11.3274 · Cited by 277
Self-citationMechanisms of diabetic vasculopathy: an overview
Cooper, M. (2001) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)01323-6 · Cited by 267
Self-citationForbes, J. M., Thallas, V., Thomas, M. C., Founds, H. W., Burns, W. C., Jerums, G., & Cooper, M. E. (2003) · The FASEB Journal · doi:10.1096/fj.02-1102fje · Cited by 263
Self-citationWendt, T., Tanji, N., Guo, J., Hudson, B. I., Bierhaus, A., Ramasamy, R., Arnold, B., Nawroth, P. P., Yan, S. F., D’Agati, V., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065100.17349.ca · Cited by 239
Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice
Flyvbjerg, A., Denner, L., Schrijvers, B. F., Tilton, R. G., Mogensen, T. H., Paludan, S. R., & Rasch, R. (2004) · Diabetes · doi:10.2337/diabetes.53.1.166 · Cited by 187
Metadata
- Authors
- Soulis, T., Cooper, M. E., Vranes, D., Bucala, R., & Jerums, G.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 1996-08
- Volume
- 50
- Issue
- 2
- Pages
- 627-634
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W1995428435
- Cited by
- 158
- References
- 0
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.